Product Code: RP-ID-10246014 |
Published Date: 21 Oct 2022 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10246014
Market Overview:
Global Human Microbiome Market-Analysis By Product (Probiotics, Prebiotics, Medical Food, Others), By Disease, Application, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024) 2022-2030
The overall human microbiome market is estimated to be USD ~500 million by the end of 2021 and is expected to register a CAGR of ~20% between 2022 and 2030. The overall human microbiome market has grown significantly in recent years, owing to the growing prevalence of diabetes, a growing geriatric population, and continued research and development by pharmaceutical companies and academia.
Additionally, the growth of sedentary lifestyles and the increasing prevalence of diabetes and chronic diseases worldwide are driving the human microbiome overall market share. These factors could give a greater impetus to the market growth during the forecast period. In addition, intestinal issues such as data generation between market players and universities and increasing treatment of diseases that can be treated with microorganisms will drive the development of the industrial cooperation market.
Human Microbiome Among the industry;s product types (probiotics, probiotics, pharmaceuticals and other products), probiotics are the human microbiome due to their proven benefits to the gut flora and patient health.
The microbiome market will continue to be the largest market during the forecast period owing to the favorable repayment policy of the government and strong health awareness. Countries such as India, China and Brazil are attractive markets for human microbes.
REPORT SCORE :
This report analyzes the global, regional and national human microbiome market and reports the human microbiome market by product (probiotics, prebiotics, medical food, etc.) (therapeutic and diagnostic). Global Human Microbiome Market, including regions (North America, Europe, Asia Pacific, ROW) and countries (USA, Canada, Mexico, UK, Germany, France, India, China, Japan, South Korea) and key findings and analysis.
This report is provided using Porter's Five Forces Analysis Framework and SWOT. It also characterizes the market attractiveness of each region, product, disease and application. The report also analyzes key industry opportunities, trends, drivers and challenges, and tracks competitive developments, strategies, mergers and acquisitions, and new product developments. Companies analyzed in this report include OptiBiotix Health Plc, Metabiomics and OSEL Inc. and PureTech Health, 4D Pharma and Synlogic Inc. and BaseClear BV, Rebiotix Inc., Ritter Pharmaceuticals, and Assembly Bioscience Inc. human microbes. Forecast period 2022-2030.
KEY AUDIENCE
Food companies, whole suppliers of the human microbiome, consulting and consulting firms, governments and policy makers, investment banks and public corporations, regulators.
OptiBiotix Health Plc, Metabiomics, OSEL Inc., PureTech Health, 4D Pharma, Synlogic Inc., BaseClear BV, Rebiotix Inc, Ritter Pharmaceuticals, Assembly Bioscience Inc
Related Reports
Proof of Quality & Reliability
